

**CREON® 5
MINIMICROSPHERES®
(Pancrelipase Delayed-release Capsules, USP)**

R_x only

1
2 500197 Rev Feb 2006

3
4 **PRESCRIBING INFORMATION**

5
6 **DESCRIPTION**

7 CREON® 5 Capsules are orally administered and contain pancrelipase (lipase 5,000 USP Units,
8 protease 18,750 USP Units and amylase 16,600 USP Units per capsule) which is of porcine
9 pancreatic origin. Each CREON 5 Capsule is filled with 124 mg of delayed-release
10 MINIMICROSPHERES®.

11
12 Inactive ingredients include dibutyl phthalate, dimethicone, hydroxypropylmethylcellulose
13 phthalate, light mineral oil and polyethylene glycol. The capsule shells contain gelatin, red iron
14 oxide, titanium dioxide, yellow iron oxide and FD & C blue No. 2. The capsule imprinting ink
15 contains dimethicone, 2-ethoxyethanol, shellac, soya lecithin, and titanium dioxide.

16
17 **CLINICAL PHARMACOLOGY**

18 The pancreatic enzymes in CREON 5 Capsules are enteric-coated to resist gastric destruction or
19 inactivation. The pancreatic enzymes catalyze the hydrolysis of fats to glycerol and fatty acids,
20 protein into proteoses and derived substances and starch into dextrans and short chain sugars.

21
22 **INDICATIONS**

23 CREON 5 Capsules are indicated for patients with pancreatic exocrine insufficiency as is often
24 associated with:

- 25 • cystic fibrosis
26 • chronic pancreatitis
27 • post-pancreatectomy
28 • post-gastrointestinal bypass surgery (e.g., Billroth II gastroenterostomy)
29 • ductal obstruction from neoplasm (e.g., of the pancreas or common bile duct)

30
31 **CONTRAINDICATIONS**

32 CREON 5 Capsules are contraindicated in the early stages of acute pancreatitis or in patients who
33 are known to be hypersensitive to pork protein.

34
35 **WARNINGS**

36 Should symptoms of hypersensitivity appear, discontinue medication and initiate symptomatic
37 and supportive therapy if necessary.

38
39 Strictures in the ileo-cecal region and/or ascending colon have been reported in cystic fibrosis
40 patients treated with high doses of high-potency pancreatic enzyme supplements containing
41 20,000 or greater USP units of lipase per capsule. The underlying mechanism is unknown, but

42 caution should be exercised when doses in excess of 6,000 USP units lipase per kg per meal fail
43 to resolve symptoms, especially in patients with a history of intestinal complications such as
44 meconium ileus equivalent, short bowel syndrome, surgery or Crohn's disease. If symptoms
45 suggestive of gastrointestinal obstruction occur, the possibility of bowel stricture should be
46 investigated including evaluation of pancreatic enzyme therapy.

47

48 **PRECAUTIONS**

49 CREON 5 Capsules MINIMICROSPHERES SHOULD NOT BE CRUSHED OR CHEWED or
50 placed on foods having a pH greater than 5.5. These can dissolve the protective enteric coating
51 resulting in early release of enzymes, irritation of oral mucosa, and/or loss of enzyme activity.

52

53 **Information for Patients**

54 CREON 5 Capsules are a pancreatic enzyme product prescribed to promote improved digestion
55 of foods, especially fat. The prescribed dosage should be taken with each meal and snack or as
56 directed by the physician. The capsules can be swallowed whole, or the contents poured on soft,
57 bland food. Care should be taken to avoid chewing or crushing of the capsule contents, which
58 can result in early release of enzymes, irritation of oral mucosa, and/or loss of enzyme activity.
59 Patients should maintain adequate fluid intake. The prescribed dose range should not be
60 exceeded without calling your doctor.

61

62 The most common adverse reactions involve the stomach and intestine including diarrhea,
63 nausea, vomiting, bloating, constipation, stomach cramps or pain. If these symptoms are
64 persistent, contact your doctor.

65

66 **Carcinogenesis, Mutagenesis, Impairment of Fertility**

67 Long-term studies in animals have not been performed to evaluate carcinogenic potential.

68

69 **Pregnancy, Category C**

70 Animal reproduction studies have not been conducted with pancrelipase. It is also not known
71 whether pancrelipase can cause fetal harm when administered to a pregnant woman or can affect
72 reproduction capacity. CREON 5 Capsules should be given to a pregnant woman only if clearly
73 needed.

74

75 **Nursing Mothers**

76 It is not known whether this drug is excreted in human milk. Because many drugs are excreted in
77 human milk, caution should be exercised when CREON 5 Capsules are administered to a nursing
78 mother.

79

80 **ADVERSE REACTIONS**

81 The most frequently reported adverse reactions to pancreatic enzyme-containing products are
82 gastrointestinal in nature which may include nausea, vomiting, bloating, cramping, constipation
83 or diarrhea. Less frequently, allergic-type reactions have also been observed. Very high doses of
84 pancreatin have been associated with hyperuricosuria and hyperuricemia.

85

86 **DOSAGE AND ADMINISTRATION**

87 Clinical experience should dictate initial starting dose. Doses should be taken during meals or
88 snacks, not before or after. Do not take without food.

89

90 **Adults and Children Over 6 Years Old**

91 Usual initial starting dosage is two to four CREON 5 Capsules per meal or snack.

92

93 **Children Under 6 Years Old**

94 The exact dosage of CREON 5 Capsules should be selected based on clinical experience for this
95 age group. Patients can be started on one to two capsules per meal or snack.

96

97 For cystic fibrosis patients, typical doses are 1,500 - 3,000 USP lipase units/kg/meal. Dosage
98 should be adjusted according to the severity of the disease, control of steatorrhea and
99 maintenance of good nutritional status. Doses in excess of 6,000 USP lipase units/kg/meal are
100 not recommended.

101

102 Dose increases, if required, should occur with careful monitoring of body weight and stool fat
103 content. When changing strengths of pancreatic enzyme products, care should be taken to
104 maintain equivalent lipase units for each divided dosage.

105

106 It is important to ensure adequate hydration of patients at all times while taking pancreatic
107 enzymes.

108

109 Where swallowing of capsules is difficult, the capsules may be carefully opened and the
110 MINIMICROSPHERES added to a small amount of soft food, with a pH less than 5.5. The soft
111 food should be swallowed immediately without chewing and followed with a glass of water or
112 juice to insure swallowing.

113

114 **HOW SUPPLIED**

115 CREON 5 MINIMICROSPHERES (Pancrelipase Delayed-release Capsules, USP) are available
116 in a two-piece gelatin capsule (orange opaque top half, blue opaque bottom half) imprinted in
117 white with "SOLVAY" and "1205". Each capsule contains tan-colored delayed-release
118 MINIMICROSPHERES of pancrelipase supplied in bottles of:

119

120 100.....NDC 0032-1205-01

121 250.....NDC 0032-1205-07

122

123 CREON 5 Capsules must be stored at 25 °C (77 °F); excursions permitted to 15°-30°C (59°-
124 86°F). [See USP Controlled Room Temperature.] PROTECT FROM MOISTURE. DO NOT
125 REFRIGERATE. Dispense in tight, light-resistant containers. For human consumption only.

126

127 **Manufactured By:**

128 Solvay Pharmaceuticals GmbH,

129 Hannover, Germany

130

131 **Marketed by:**

132 **Solvay**

133 **Pharmaceuticals, Inc.**

134 Marietta, GA 30062

135

136 500197 Rev Feb 2006

137

138 MINIMICROSPHERES is

139 a registered trademark of

140 Solvay Pharmaceuticals, Inc.

141

142 © 2006 Solvay Pharmaceuticals, Inc.